The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
about
The immune pathogenesis of scleroderma: context is everythingRole of redoximiRs in fibrogenesisOxidative damage and antioxidative therapy in systemic sclerosisNADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agentsFox-2 protein regulates the alternative splicing of scleroderma-associated lysyl hydroxylase 2 messenger RNAKnockout of endothelial cell-derived endothelin-1 attenuates skin fibrosis but accelerates cutaneous wound healing.Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13The Tumor Necrosis Factor Superfamily Molecule LIGHT Promotes Keratinocyte Activity and Skin Fibrosis.CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.How does endothelial cell injury start? The role of endothelin in systemic sclerosis.The role of B cells in systemic sclerosis.Geniposide inhibited endothelial-mesenchymal transition via the mTOR signaling pathway in a bleomycin-induced scleroderma mouse model.Abnormal B lymphocyte activation and function in systemic sclerosis.B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.Interstitial lung disease in systemic sclerosis: current and future treatment.Unifying mechanism for different fibrotic diseases.Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.Oxidative Stress and Skin Fibrosis.Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma.N-acetylcysteine attenuates subcutaneous administration of bleomycin-induced skin fibrosis and oxidative stress in a mouse model of scleroderma.A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis.Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells.Treatment of orbital vascular malformations with intralesional injection of pingyangmycin.A convenient method for producing the bleomycin-induced mouse model of scleroderma by weekly injections using a methylcellulose gel.Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.Impaired wound healing in bleomycin-induced murine scleroderma: a new model of wound retardation.Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
P2860
Q24633658-1E369AE8-6635-4F13-8EFF-9235BF7610F5Q26776555-926FF3CD-8E40-4E29-8AE3-98D3459E39BCQ28394733-18AAAF96-4801-4A73-886F-416A32B9A36AQ33705075-43EB3D49-1195-4CE6-B1E9-0DDC9CED64BFQ34043151-5A9A063D-CAC1-4E87-AA8E-B63FAD3AA3AEQ35172697-C6B91558-582A-40BA-A8D1-01CBB8278316Q35669762-50C92005-E7EE-4031-9DA8-F91E2C3812E3Q35858686-3ABC423D-FD55-463D-9E8B-5E10811A91FFQ36691117-AA17BB3E-A5A3-4F1F-BB4B-B7F4D814E3A9Q36927745-DBAB244F-56D7-487A-93C0-3D8C0362A52DQ37586886-7B1384C0-522B-45D7-9890-650B20474633Q37732969-5CCC5BDD-5E9A-428C-9C63-65800ADC4813Q38352418-64E27D75-9691-42D3-9FAF-F5AF63DE9586Q38701988-B461BDD5-062B-4889-A0D6-0449B5913CE7Q38773637-41648937-A42E-4676-80CE-72E96484A919Q38829704-42BBB9F7-6FE8-45A8-9E03-8165A1280436Q41980258-40FF6A5F-5B01-4BEA-8BFB-06D432D19FB4Q42984072-9B565048-1FE3-4EC6-8F7B-05A19063BC2FQ43833385-48E1D080-CCE8-4EFE-925D-2331E20B73EEQ44824704-E78629D7-48E8-497B-BB74-B4266559A863Q46768735-C6A25BC7-D65C-4F8F-B9EC-37AC3F581805Q49989946-68B4E461-C9CD-46EF-997D-E6683C4ED1F2Q50858690-8955137C-1D11-4239-8078-94D878716124Q51484774-B5011BCD-7F6C-418A-B58D-7633A779411FQ51672074-8A487BE1-7EDC-436D-8A35-F92248299687Q53165286-9371A0DF-3C92-4CD7-8618-D10FB40089BEQ53246701-E5889ED4-B6E9-4092-AE20-3B29B42CDCFFQ53512767-5B4CE1BC-990B-44E4-9011-CE29A975AF0A
P2860
The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The bleomycin-induced sclerode ...... for scleroderma pathogenesis?
@ast
The bleomycin-induced sclerode ...... for scleroderma pathogenesis?
@en
type
label
The bleomycin-induced sclerode ...... for scleroderma pathogenesis?
@ast
The bleomycin-induced sclerode ...... for scleroderma pathogenesis?
@en
prefLabel
The bleomycin-induced sclerode ...... for scleroderma pathogenesis?
@ast
The bleomycin-induced sclerode ...... for scleroderma pathogenesis?
@en
P2860
P1476
The bleomycin-induced sclerode ...... for scleroderma pathogenesis?
@en
P2093
Toshiyuki Yamamoto
P2860
P2888
P304
P356
10.1007/S00403-005-0635-Z
P577
2006-01-10T00:00:00Z